# Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel)

> **NCT05322889** · PHASE2 · COMPLETED · sponsor: **Dr. Frank Behrens** · enrollment: 35 (actual)

## Conditions studied

- Neuropathic Pain
- Chemotherapy Effect

## Interventions

- **DRUG:** Telmisartan tablets

## Key facts

- **NCT ID:** NCT05322889
- **Lead sponsor:** Dr. Frank Behrens
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-09
- **Primary completion:** 2022-10-04
- **Final completion:** 2023-06-30
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05322889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05322889, "Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05322889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*